According to Zacks, “MDxHealth SA is a healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. MDxHealth SA is based in Belgium. “
NASDAQ:MDXH opened at $7.88 on Thursday. The company’s 50 day moving average is $8.11. MDxHealth has a 52 week low of $7.01 and a 52 week high of $13.17.
MDxHealth Company Profile (Get Rating)
MDxHealth SA operates as a molecular diagnostics company in Belgium, the Netherlands, Spain, Poland, Italy, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients.
- Get a free copy of the StockNews.com research report on MDxHealth (MDXH)
- Carl Icahn Buys More Xerox
- Xerox Holdings Stock is a Value Play
- The Kraft Heinz Turnaround Story Gains Momentum
- Microsoft (NASDAQ: MSFT) Saves The Day, For Now
- Las Vegas Sands Stock Could be a Winning Bet Down Here
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.